Krystal Biotech, Inc.
Krystal Biotech, Inc. (KRYS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · KRYS · as of Sep 30, 2025
Ownership Breakdown
299
Institutional Holders
▲ 10 vs Q2
$4.94B
Total Inst. Value
▲ $1.13B vs Q2
29.48M
Shares Outstanding
freeFloat 79.28%
28.01M
13F Shares Held
▲ 348,479 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
KRYS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC biological products, (no diagnostic substances) | 4.34M | 15.02% | 15.02% | $766.40B | Nov 13, 2025 | ▲ 6.7K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 3.83M | 13.26% | 13.26% | $676.84B | Nov 12, 2025 | ▼ 11.0K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.79M | 9.66% | 9.66% | $492.91B | Nov 7, 2025 | ▼ 30.7K |
AVORO CAPITAL ADVISORS LLC biological products, (no diagnostic substances) | 2.78M | 9.61% | 9.61% | $490.36B | Nov 14, 2025 | ▲ 117.8K |
STATE STREET CORP biological products, (no diagnostic substances) | 1.40M | 4.83% | 4.83% | $246.43B | Nov 14, 2025 | ▲ 40.6K |
SOLEUS CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.02M | 3.52% | 3.52% | $179.85B | Nov 14, 2025 | ▲ 95.9K |
CAPITAL WORLD INVESTORS biological products, (no diagnostic substances) | 809.2K | 2.80% | 2.80% | $142.86B | Nov 13, 2025 | ▼ 133.0K |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. biological products, (no diagnostic substances) | 688.5K | 2.38% | 2.38% | $121.53B | Nov 14, 2025 | — held |
REDMILE GROUP, LLC biological products, (no diagnostic substances) | 661.4K | 2.29% | 2.29% | $116.75B | Nov 14, 2025 | ▼ 2.1K |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 637.0K | 2.20% | 2.20% | $112.45B | Nov 14, 2025 | ▲ 602.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
25
Increased
+1.85M shares0
New Positions
first time holders19
Decreased
−877.7K shares0
Sold Out
fully exitedNet shares change (top 50)
+973.4K
+1.85M / −877.7K
Net new holders
+6
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
KRYS insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
23
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 320 | $300.75 | $96.2K | 1.40M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 593 | $302.25 | $179.2K | 1.40M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 247 | $303.17 | $74.9K | 1.40M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 400 | $304.89 | $122.0K | 1.40M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 480 | $305.87 | $146.8K | 1.40M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 1,348 | $307.09 | $414.0K | 1.40M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 12,729 | $307.81 | $3.92M | 1.39M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 3,803 | $308.89 | $1.17M | 1.38M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 2,801 | $309.95 | $868.2K | 1.38M | Form 4 ↗ |
Krishnan Suma President, R&D | Jun 4, 2026 | Sale | 2,039 | $310.94 | $634.0K | 1.38M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Krystal Biotech, Inc. (KRYS) is primarily owned by institutional investors, who hold approximately 95.0% of total shares outstanding. Company insiders own approximately 20.72%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Krystal Biotech, Inc. is FMR LLC, holding approximately 4.34 million shares — equal to 15.02% of outstanding shares — as of September 30, 2025.
A total of 299 institutional investors currently hold KRYS stock, with a combined institutional value of approximately $4.94 billion as of the most recent 13F filing period.
Frequently asked questions
KRYS ownershipKrystal Biotech, Inc. (KRYS) is primarily owned by institutional investors, who hold approximately 95.0% of shares. The largest shareholder is FMR LLC with a 15.02% stake. Company insiders hold 20.72%. Data sourced from SEC Form 13F as of September 30, 2025.